To test the contribution of cancer cell-derived LIF to the induction of myMAFs in vitro, primary HStCs were exposed to cancer cell CM, pre-treated with IgG or LIF neutralising antibody (LIF-nAb), and supplemented with recombinant progranulin (Fig. 5A). The gene discussed is LIF; the disease is cancer.